PMID: 6540188Jul 1, 1984Paper

Dibromodulcitol, mitomycin C and vinblastine (DMV) chemotherapy in advanced breast cancer

European Journal of Cancer & Clinical Oncology
A HowellI J Moneypenny

Abstract

A combination of dibromodulcitol 500 mg orally, mitomycin C 10 mg i.v. and vinblastine 10 mg i.v. all given on day 1 and repeated every 4 weeks was given to 40 patients with advanced breast cancer. All but one had received previous endocrine therapy. The response rate (CR + PR) in 24 previously untreated patients was 66% and was 37% in 16 previously treated patients. The survival of responders was significantly longer than non-responders. Thirty-two per cent of patients experienced nausea and vomiting. There was little myelosuppression or thrombocytopenia on the day of starting a new course of therapy but the haemoglobin dropped by 2 g/dl in 32% of patients during therapy. Thus DMV is a relatively non-toxic active regimen for patients with advanced breast cancer.

References

Sep 1, 1979·Cancer Treatment Reviews·N E MischlerD C Tormey
Sep 1, 1976·Cancer Treatment Reviews·S T Crooke, W T Bradner
Jan 1, 1976·Medical and Pediatric Oncology·G R WiseT E Godfrey
Dec 1, 1982·Cancer Treatment Reviews·G FalksonH C Falkson

❮ Previous
Next ❯

Citations

Jan 1, 1990·Cancer Chemotherapy and Pharmacology·J BellmuntL A Solé
Dec 1, 1985·European Journal of Cancer & Clinical Oncology·R J Paridaens
Sep 1, 1987·European Journal of Cancer & Clinical Oncology·A DeesG Stoter

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.